MétaCan
Menu
Back to cohort
Record W4415397515 · doi:10.24911/ijmdc.51-1737107151

To evaluate and compare the efficacy of newer antidiabetic medications on cardiovascular outcomes

2025· article· W4415397515 on OpenAlexaboutno aff
Omar Bahamdan, Asayel Alomri, Hussain Lajami, Naser Alsubaei, Mohammed Altuwaijri, Abdullah Alhajri, Jawad Uliwat, Assim Osman

Bibliographic record

VenueInternational Journal of Medicine in Developing Countries · 2025
Typearticle
Language
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsnot available
Fundersnot available
KeywordsLiraglutideSemaglutideGlycemicDiabetes mellitusDiscontinuationAdverse effectType 2 diabetesRandomized controlled trialClinical trial

Abstract

fetched live from OpenAlex

Millions of individuals worldwide suffer from diabetes mellitus, especially type 2 diabetes (T2D), which significantly increases morbidity and death. Diabetes reduces a person's functioning and quality of life, and because of comor bidities, including cardiovascular (CV) problems, it often leads to early mortality. The study searched for research on the relative effectiveness of more recent antidiabetic drugs on CV outcomes in individuals with T2D mellitus using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search method comprised medical subject headers and keywords. The RayymanTM tool was used to assess the retrieved articles for eligibility and exclusion criteria. The Newcastle-Ottawa Quality Assessment Scale and the Cochrane risk of bias assessment tool for randomized controlled trials were used to assess the quality and risk of bias. Glucagon-like Peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide demonstrated significant cardioprotective effects in high-risk T2D patients. These medications reduced major adverse cardiovascular events and mortality rates compared to traditional therapies. Efpeglenatide and tirzepatide exhibited superior glycemic control and weight reduction benefits, while also improving renal outcomes. However, gastrointestinal side effects were more common, leading to treatment discontinuation in some cases. Newer antidiabetic agents, particularly GLP-1 receptor agonists, offer substantial CV and metabolic benefits for T2D management, especially in high-risk individuals. These medications significantly reduce the risk of CV death and major CV events while improving glycemic control. Future research should prioritize long-term outcomes and safety profiles to enhance therapeutic strategies in diabetes care.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.422
Threshold uncertainty score0.697

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.345
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueInternational Journal of Medicine in Developing CountriesSame topicDiabetes Treatment and ManagementFrench-language works237,207